Valuation: Ind-Swift Laboratories Limited

Market Cap 32.95B 346M 310M 287M 260M 486M 492M 3.43B 1.37B 17.24B 1.3B 1.27B 54.74B P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 28.74B 302M 271M 250M 227M 424M 429M 2.99B 1.19B 15.04B 1.13B 1.11B 47.75B EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
32.35%
Yield 2025 *
-
Yield 2026 -
1 day+2.75%
1 week+7.69%
Current month-2.52%
1 month-6.28%
3 months+57.96%
6 months+182.17%
Current year+329.89%
1 week 316
Extreme 316
382
1 month 316
Extreme 316
424.75
Current year 87.25
Extreme 87.25
424.75
1 year 87.15
Extreme 87.15
424.75
3 years 68.72
Extreme 68.72
424.75
5 years 52.65
Extreme 52.65
424.75
10 years 15
Extreme 15
424.75
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 15/06/2011
Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 23/03/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/9/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+2.75%+7.69%+265.25%+344.00% 338M
+0.50%+0.36%+55.89%+129.96% 1,143B
+0.86%+4.50%+42.43%+86.15% 647B
-0.14%-1.07%+25.42%+105.85% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-4.97%+60.15%+37.06% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+2.94%+55.18%+72.74% 242B
+0.08%+1.72%+32.15%+107.78% 197B
Average +0.77%+1.24%+61.26%+103.16% 402.79B
Weighted average by Cap. +0.72%+0.71%+42.65%+89.04%

Financials

2025 2026
Net sales 5.62B 58.98M 52.92M 48.92M 44.31M 82.78M 83.78M 585M 233M 2.94B 221M 217M 9.33B 6.49B 68.16M 61.15M 56.54M 51.2M 95.66M 96.82M 676M 269M 3.4B 256M 250M 10.78B
Net income 2.5B 26.3M 23.6M 21.82M 19.76M 36.91M 37.36M 261M 104M 1.31B 98.69M 96.61M 4.16B 431M 4.53M 4.06M 3.76M 3.4M 6.36M 6.43M 44.91M 17.89M 226M 16.99M 16.63M 716M
Net Debt -4.27B -44.79M -40.18M -37.15M -33.65M -62.86M -63.62M -444M -177M -2.23B -168M -165M -7.09B -4.21B -44.23M -39.68M -36.69M -33.23M -62.08M -62.83M -439M -175M -2.2B -166M -162M -7B
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
28/10/26 ₹378.95 +2.75% 589,736
27/10/26 ₹368.80 +9.42% 850,817
26/10/26 ₹337.05 +2.93% 414,766
23/10/26 ₹327.45 -5.18% 658,248
22/10/26 ₹345.35 +0.83% 269,569
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock